SUBSCRIBERS
Merck weighing acquisition of Cubist for more than US$7b: sources
Deal, if announced, would be another multibillion-dollar health care transaction in a banner year for M&A
Published Sun, Dec 7, 2014 · 09:50 PM
New York
DRUGMAKER Merck & Co is in talks to acquire the biopharmaceuticals company Cubist for more than US$7 billion, according to people briefed on the matter.
The deal, if announced, would represent another multibillion-dollar health care transaction in a banner year for mergers and acquisitions in the industry.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Chinese tariffs could leave cognac makers with too much brandy
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales